Novartis Cancer Drug Is Approved With $475,000 Price Tag

The approval of Novartis AG’s breakthrough therapy for a deadly form of leukemia opened the door to a new class of treatments even as its $475,000 price tag reignited the debate on how to value potentially life-saving drugs. Bloomberg's Anna Edney reports on "Bloomberg Markets." (Source: Bloomberg)

Full Show: Surveillance (07/27)
44:34 - Bloomberg Surveillance hosted by Tom Keene and Francine Lacqua. Guests include Andrew Bailey, chief executive officer at Financial Conduct Authority, Severin Schwan, chief executive officer at Roche Holding AG, and Richard Clarida, global strategic adviser at Pimco. (Source: Bloomberg)
  • Roche CEO Schwan on Profit Forecast, Drug Pipeline
  • Full Show: Bloomberg Daybreak: Americas (07/25)
  • Full Show: Surveillance (07/25)